Novo Nordisk A/S
Healthy Returns: How competitive can Roche be in the weight loss drug market?
Headquarters of Roche, multinational pharmaceutical industry on December 27, 2021 in Madrid, Spain. Cristina Arias | Cover | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Good afternoon! Roche is one of several drugmakers […]
Read More
Eli Lilly to invest $1.8 billion to expand manufacturing for weight loss, diabetes and Alzheimer’s drugs
A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024. Scott Olson | Getty Images Eli Lilly on Thursday said it will invest $1.8 billion to boost manufacturing for its newly approved Alzheimer’s drug and highly popular weight loss and diabetes treatments, among other medicines, […]
Read More
Healthy Returns: More than 50 million privately insured adults could be eligible for GLP-1 drugs
Weight loss syringes of the brands “Wegovy”, “Ozempic” and “Mounjaro” are sold at In der Achat Apotheke in Mitte, Germany. Picture Alliance | Picture Alliance | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future […]
Read More
Healthy Returns: Eli Lilly could soon become the first $1 trillion health-care stock
A sign with the company logo outside the headquarters of Eli Lilly and Company in Indianapolis, Indiana, March 17, 2024. Scott Olson | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Earlier this […]
Read More
Weight loss drugs cut Covid-19 deaths, study finds
People taking the key component of blockbuster weight loss drugs Ozempic and Wegovy were less likely to die of Covid-19 or suffer adverse effects from the virus, researchers found in a new study. People who were already being treated with a 2.4 mg dose of the drug semaglutide — the active ingredient in pharma titan […]
Read More
Eli Lilly releases new form of weight loss drug Zepbound for half the price to boost access, supply
Eli Lilly on Tuesday released a new form of its weight loss drug Zepbound for roughly half its usual monthly list price to reach millions of patients without insurance coverage for the popular injection, such as those with Medicare. The move also aims to expand the supply of Zepbound in the U.S. as demand skyrockets, […]
Read More
Health-care system Sesame to offer compounded versions of Wegovy through new $249 weight loss program
Health-care marketplace Sesame on Wednesday announced a new clinical weight loss program that will help eligible consumers access compounded versions of Novo Nordisk‘s blockbuster obesity drug Wegovy for $249 per month. Sesame allows patients to book and pay for appointments with doctors and specialists directly through its website, so it cuts out middlemen such as […]
Read More
Eli Lilly’s weight loss drug slashes the risk of developing diabetes in long-term trial
An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March 28, 2024. Shelby Knowles | Bloomberg | Getty Images Eli Lilly’s highly popular weight loss drug reduced the risk of developing Type 2 diabetes by 94% in obese or overweight adults with pre-diabetes compared to […]
Read More
Novo Nordisk vs. Eli Lilly: Analysts weigh in as the obesity-drug battle heats up
COPENHAGEN, Denmark — Analysts are paying close attention to Novo Nordisk and Eli Lilly , as the battle to dominate the weight loss drug market heats up. Europe’s largest company Novo Nordisk has dominated headlines since anti-obesity medication took off. It produces weight-loss and diabetes drugs Wegovy and Ozempic and saw its shares rise exponentially […]
Read More
S&P 500 will be closer to 6,000 by year-end, Morgan Stanley’s Slimmon says, naming stocks to buy
Markets have been very rocky lately, but Morgan Stanley Investment Management’s Andrew Slimmon has an idea of how they could go from here. He says the market could “be consistent with 2023,” after much volatility in the past few weeks. In late July, both the S & P 500 and the Nasdaq dived to a […]
Read More